Investigational Drug Information for Ecopipam
✉ Email this page to a colleague
What is the development status for investigational drug Ecopipam?
Ecopipam is an investigational drug.
There have been 18 clinical trials for Ecopipam.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2022.
The most common disease conditions in clinical trials are Tourette Syndrome, Syndrome, and Childhood-Onset Fluency Disorder. The leading clinical trial sponsors are Emalex Biosciences Inc., Psyadon Pharma, and Nuventra.
Summary for Ecopipam
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 302 |
| WIPO Patent Applications | 219 |
| Japanese Patent Applications | 162 |
| Clinical Trial Progress | Phase 2 (2022-12-01) |
| Vendors | 24 |
Recent Clinical Trials for Ecopipam
| Title | Sponsor | Phase |
|---|---|---|
| Drug Interaction Study | Cambridge Cognition Ltd | Phase 1 |
| Drug Interaction Study | Syneos Health | Phase 1 |
| Drug Interaction Study | Emalex Biosciences Inc. | Phase 1 |
Clinical Trial Summary for Ecopipam
Top disease conditions for Ecopipam
Top clinical trial sponsors for Ecopipam
US Patents for Ecopipam
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
